Certain breast CA patients benefit from adjuvant capecitabine

June 1, 2017

(HealthDay)—Capecitabine (Xeloda) can extend the lives of patients with human epidermal growth factor receptor 2 (HER2)-negative breast cancer who have residual invasive disease after receipt of neoadjuvant chemotherapy, according to a study published in the June 1 issue of the New England Journal of Medicine.

The new trial focused on 910 women with HER2-negative residual invasive after neoadjuvant chemotherapy. Participants received standard post-surgical treatment either with capecitabine or without (the control group).

The researchers found that capecitabine was associated with a reduced risk of relapse or death (30 percent over five years). At that point, 74.1 percent were still alive and recurrence-free, versus 67.6 percent of women in the control group. Five years later, 89.2 percent of capecitabine patients were still alive, compared with 83.6 percent of control patients. Among women with , 78.8 percent of capecitabine patients were alive after five years, compared with 70.3 percent of control patients.

"After standard containing anthracycline, taxane, or both, the addition of adjuvant capecitabine therapy was safe and effective in prolonging disease-free survival and overall survival among patients with HER2-negative breast cancer who had residual invasive disease on pathological testing," the authors conclude.

Explore further: Capecitabine improved outcomes for breast cancer patients with disease after presurgery chemo

More information: Abstract/Full Text (subscription or payment may be required)

Related Stories

Capecitabine improved outcomes for breast cancer patients with disease after presurgery chemo

December 9, 2015
Treatment with the chemotherapy agent capecitabine increased disease-free survival for women with HER2-negative breast cancer that was not eliminated by presurgery chemotherapy, according to results from the phase III CREATE-X ...

Capecitabine monotherapy does not improve survival in elderly patients with early-stage breast cancer

December 12, 2014
In elderly breast cancer patients with moderate- to high-risk early-stage disease for whom standard chemotherapy is too toxic, the chemotherapy capecitabine, which causes fewer side effects than the standard chemotherapy ...

Study finds greater potential benefit in overall survival for eribulin compared with capecitabine

June 12, 2013
Subgroup analyses from a phase III clinical trial comparing a newer chemotherapy agent called eribulin mesylate, with capecitabine, a standard chemotherapy medication in women with previously treated metastatic breast cancer, ...

Axillary pCR linked to improved breast cancer survival

January 5, 2016
(HealthDay)—For women with breast cancer treated with primary systemic chemotherapy (PST), achieving axillary pathologic complete response (pCR) is associated with improved survival, according to a study published online ...

Study compares standard against newer treatment in women whose breast cancer has spread

December 7, 2012
Results from a phase III clinical trial comparing a newer chemotherapy agent called eribulin mesylate with capecitabine, a standard drug used for chemotherapy today in women with previously treated metastatic breast cancer, ...

Neratinib active in HER2-positive, HR-negative breast cancer

July 7, 2016
(HealthDay)—Neratinib and veliparib-carboplatin appear to be effective in women with specific subtypes of breast cancer, according to two studies published online July 6 in The New England Journal of Medicine.

Recommended for you

Daily low-dose aspirin may be weapon against ovarian cancer

July 20, 2018
(HealthDay)— One low-dose aspirin a day could help women avoid ovarian cancer or boost their survival should it develop, two new studies suggest.

Discovery of kidney cancer driver could lead to new treatment strategy

July 19, 2018
University of North Carolina Lineberger Comprehensive Cancer Center scientists have uncovered a potential therapeutic target for kidney cancers that have a common genetic change. Scientists have known this genetic change ...

High fruit and vegetable consumption may reduce risk of breast cancer, especially aggressive tumors

July 19, 2018
Women who eat a high amount of fruits and vegetables each day may have a lower risk of breast cancer, especially of aggressive tumors, than those who eat fewer fruits and vegetables, according to a new study led by researchers ...

Sunscreen reduces melanoma risk by 40 per cent in young people

July 19, 2018
A world-first study led by University of Sydney has found that Australians aged 18-40 years who were regular users of sunscreen in childhood reduced their risk of developing melanoma by 40 percent, compared to those who rarely ...

Analysis of prostate tumors reveals clues to cancer's aggressiveness

July 19, 2018
Using genetic sequencing, scientists have revealed the complete DNA makeup of more than 100 aggressive prostate tumors, pinpointing important genetic errors these deadly tumors have in common. The study lays the foundation ...

Complementary medicine for cancer can decrease survival

July 19, 2018
People who received complementary therapy for curable cancers were more likely to refuse at least one component of their conventional cancer treatment, and were more likely to die as a result, according to researchers from ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.